Expressing support for the designation of November as "Complex Regional Pain Syndrome and Reflex Sympathetic Dystrophy Syndrome Awareness Month".

Legislative Summary: H.Res. 903

Overview

H.Res. 903 is a House Resolution introduced during the 119th Congress to formally express support for designating November as "Complex Regional Pain Syndrome and Reflex Sympathetic Dystrophy Syndrome Awareness Month."

Unlike a traditional bill that creates new laws or allocates funding, this resolution is a formal expression of the House of Representatives' support for increasing public and medical awareness of a specific rare disease.

Purpose and Intent

The primary goal of this resolution is to bring attention to Complex Regional Pain Syndrome (CRPS) and Reflex Sympathetic Dystrophy Syndrome (RSD). By designating a dedicated awareness month, the resolution aims to:
* Increase Visibility: Highlight a rare, neuro-inflammatory syndrome that is often obscure and poorly understood.
* Improve Patient Outcomes: Encourage earlier and more accurate diagnoses to prevent the condition from becoming debilitating.
* Advocate for Research: Emphasize the critical need for new diagnostics, treatments, and a cure, noting that there are currently no FDA-approved treatments for CRPS.

Key Highlights of the Condition

The resolution provides a factual basis for the designation by noting several key aspects of CRPS/RSD:
* Symptoms: Intense chronic pain, swelling, vascular changes, and functional impairment of limbs, often following a trauma, infection, or surgery.
* Demographics: The condition is significantly more common in women than men (a ratio of 3.5:1), particularly post-menopausal women.
* Prevalence: It is a rare disorder, occurring in approximately 5 to 29 per 100,000 individuals worldwide.
* Challenges: Patients often face difficulty accessing specialized care and must coordinate treatment across multiple medical specialties due to the systemic nature of the disease.

Key Provisions and Goals

The resolution specifically calls for the recognition of five critical areas of improvement:
1. Awareness: Increasing general knowledge of the syndrome.
2. Diagnosis: Promoting the importance of early and accurate detection.
3. Research: Advancing scientific study into the causes and effects of the disease.
4. Development: Creating new treatments, diagnostics, and eventual cures.
5. Regulatory Pathways: Identifying and utilizing FDA pathways (such as the Accelerated Approval Pathway) to speed up the development of drugs for "ultrarare" diseases.

Affected Parties

• Patients and Caregivers: Provides hope and a platform for those suffering from the disability associated with CRPS/RSD.
• Medical Professionals: Encourages a focus on early diagnosis and specialized treatment.
• Researchers and Pharmaceutical Developers: Highlights the need for innovation and the use of rare-disease regulatory frameworks.

Procedural Status

• Introduced: November 20, 2025.
• Sponsors: Rep. Paul Tonko and Rep. Mariannette Miller-Meeks.
• Current Status: Referred to the House Committee on Energy and Commerce.